 | • レポートコード：MRC2Q12-19386 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、組換えインスリン類似体の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に組換えインスリン類似体のグローバル市場のxxx％を占める「即効性」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「1型糖尿病」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 組換えインスリン類似体の中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの組換えインスリン類似体市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 組換えインスリン類似体のグローバル主要プレイヤーには、Novo Nordisk A/S、Eli Lilly and Company、Sanofi、Gan & Lee Pharmaceuticals Co., Ltd、The United Laboratories International Holdings Limited、Tonghua Dongbao Pharmaceutical Co., Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 組換えインスリン類似体市場は、種類と用途によって区分されます。世界の組換えインスリン類似体市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 即効性、中効性、持続性、超持続性 【用途別セグメント】 1型糖尿病、2型糖尿病 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 組換えインスリン類似体製品概要 - 種類別市場（即効性、中効性、持続性、超持続性） - 用途別市場（1型糖尿病、2型糖尿病） - 調査の目的 ・エグゼクティブサマリー - 世界の組換えインスリン類似体販売量予測2017-2028 - 世界の組換えインスリン類似体売上予測2017-2028 - 組換えインスリン類似体の地域別販売量 - 組換えインスリン類似体の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別組換えインスリン類似体販売量 - 主要メーカー別組換えインスリン類似体売上 - 主要メーカー別組換えインスリン類似体価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（即効性、中効性、持続性、超持続性） - 組換えインスリン類似体の種類別販売量 - 組換えインスリン類似体の種類別売上 - 組換えインスリン類似体の種類別価格 ・用途別市場規模（1型糖尿病、2型糖尿病） - 組換えインスリン類似体の用途別販売量 - 組換えインスリン類似体の用途別売上 - 組換えインスリン類似体の用途別価格 ・北米市場 - 北米の組換えインスリン類似体市場規模（種類別、用途別） - 主要国別の組換えインスリン類似体市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの組換えインスリン類似体市場規模（種類別、用途別） - 主要国別の組換えインスリン類似体市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の組換えインスリン類似体市場規模（種類別、用途別） - 主要国別の組換えインスリン類似体市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の組換えインスリン類似体市場規模（種類別、用途別） - 主要国別の組換えインスリン類似体市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの組換えインスリン類似体市場規模（種類別、用途別） - 主要国別の組換えインスリン類似体市場規模（トルコ、サウジアラビア） ・企業情報 Novo Nordisk A/S、Eli Lilly and Company、Sanofi、Gan & Lee Pharmaceuticals Co., Ltd、The United Laboratories International Holdings Limited、Tonghua Dongbao Pharmaceutical Co., Ltd ・産業チェーン及び販売チャネル分析 - 組換えインスリン類似体の産業チェーン分析 - 組換えインスリン類似体の原材料 - 組換えインスリン類似体の生産プロセス - 組換えインスリン類似体の販売及びマーケティング - 組換えインスリン類似体の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 組換えインスリン類似体の産業動向 - 組換えインスリン類似体のマーケットドライバー - 組換えインスリン類似体の課題 - 組換えインスリン類似体の阻害要因 ・主な調査結果 |
Recombinant insulin analogues are not easy to cause heterogenous allergic reaction in patients, with small side effects; It can simulate the physiological insulin secretion curve of human body, accurately adjust the blood glucose concentration of human body, reduce the risk of hypoglycemia, and further improve the safety and effectiveness.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Recombinant Insulin Analogue is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Recombinant Insulin Analogue is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Recombinant Insulin Analogue is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Recombinant Insulin Analogue include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited and Tonghua Dongbao Pharmaceutical Co., Ltd, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Recombinant Insulin Analogue manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Recombinant Insulin Analogue market. Further, it explains the major drivers and regional dynamics of the global Recombinant Insulin Analogue market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Gan & Lee Pharmaceuticals Co., Ltd
The United Laboratories International Holdings Limited
Tonghua Dongbao Pharmaceutical Co., Ltd
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Recombinant Insulin Analogue Segment by Type
Quick-Acting
Medium Effect
Long-Lasting
Super Long-Acting
Recombinant Insulin Analogue Segment by Application
Type 1 Diabetes
Type 2 Diabetes
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Recombinant Insulin Analogue market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Recombinant Insulin Analogue, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Recombinant Insulin Analogue, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Recombinant Insulin Analogue, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Recombinant Insulin Analogue sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Recombinant Insulin Analogue market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Recombinant Insulin Analogue sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited and Tonghua Dongbao Pharmaceutical Co., Ltd, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Recombinant Insulin Analogue in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Recombinant Insulin Analogue manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Insulin Analogue sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Recombinant Insulin Analogue Product Introduction
1.2 Market by Type
1.2.1 Global Recombinant Insulin Analogue Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Quick-Acting
1.2.3 Medium Effect
1.2.4 Long-Lasting
1.2.5 Super Long-Acting
1.3 Market by Application
1.3.1 Global Recombinant Insulin Analogue Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Type 1 Diabetes
1.3.3 Type 2 Diabetes
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Recombinant Insulin Analogue Sales Estimates and Forecasts 2017-2028
2.2 Global Recombinant Insulin Analogue Revenue Estimates and Forecasts 2017-2028
2.3 Global Recombinant Insulin Analogue Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Recombinant Insulin Analogue Sales by Region
2.4.1 Global Recombinant Insulin Analogue Sales by Region (2017-2022)
2.4.2 Global Sales Recombinant Insulin Analogue by Region (2023-2028)
2.5 Global Recombinant Insulin Analogue Revenue by Region
2.5.1 Global Recombinant Insulin Analogue Revenue by Region (2017-2022)
2.5.2 Global Recombinant Insulin Analogue Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Recombinant Insulin Analogue Sales by Manufacturers
3.1.1 Global Top Recombinant Insulin Analogue Manufacturers by Sales (2017-2022)
3.1.2 Global Recombinant Insulin Analogue Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Insulin Analogue in 2021
3.2 Global Recombinant Insulin Analogue Revenue by Manufacturers
3.2.1 Global Recombinant Insulin Analogue Revenue by Manufacturers (2017-2022)
3.2.2 Global Recombinant Insulin Analogue Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Recombinant Insulin Analogue Revenue in 2021
3.3 Global Recombinant Insulin Analogue Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Recombinant Insulin Analogue Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Recombinant Insulin Analogue Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Recombinant Insulin Analogue Sales by Type
4.1.1 Global Recombinant Insulin Analogue Historical Sales by Type (2017-2022)
4.1.2 Global Recombinant Insulin Analogue Forecasted Sales by Type (2023-2028)
4.1.3 Global Recombinant Insulin Analogue Sales Market Share by Type (2017-2028)
4.2 Global Recombinant Insulin Analogue Revenue by Type
4.2.1 Global Recombinant Insulin Analogue Historical Revenue by Type (2017-2022)
4.2.2 Global Recombinant Insulin Analogue Forecasted Revenue by Type (2023-2028)
4.2.3 Global Recombinant Insulin Analogue Revenue Market Share by Type (2017-2028)
4.3 Global Recombinant Insulin Analogue Price by Type
4.3.1 Global Recombinant Insulin Analogue Price by Type (2017-2022)
4.3.2 Global Recombinant Insulin Analogue Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Recombinant Insulin Analogue Sales by Application
5.1.1 Global Recombinant Insulin Analogue Historical Sales by Application (2017-2022)
5.1.2 Global Recombinant Insulin Analogue Forecasted Sales by Application (2023-2028)
5.1.3 Global Recombinant Insulin Analogue Sales Market Share by Application (2017-2028)
5.2 Global Recombinant Insulin Analogue Revenue by Application
5.2.1 Global Recombinant Insulin Analogue Historical Revenue by Application (2017-2022)
5.2.2 Global Recombinant Insulin Analogue Forecasted Revenue by Application (2023-2028)
5.2.3 Global Recombinant Insulin Analogue Revenue Market Share by Application (2017-2028)
5.3 Global Recombinant Insulin Analogue Price by Application
5.3.1 Global Recombinant Insulin Analogue Price by Application (2017-2022)
5.3.2 Global Recombinant Insulin Analogue Price Forecast by Application (2023-2028)
6 North America
6.1 North America Recombinant Insulin Analogue Market Size by Type
6.1.1 North America Recombinant Insulin Analogue Sales by Type (2017-2028)
6.1.2 North America Recombinant Insulin Analogue Revenue by Type (2017-2028)
6.2 North America Recombinant Insulin Analogue Market Size by Application
6.2.1 North America Recombinant Insulin Analogue Sales by Application (2017-2028)
6.2.2 North America Recombinant Insulin Analogue Revenue by Application (2017-2028)
6.3 North America Recombinant Insulin Analogue Market Size by Country
6.3.1 North America Recombinant Insulin Analogue Sales by Country (2017-2028)
6.3.2 North America Recombinant Insulin Analogue Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Recombinant Insulin Analogue Market Size by Type
7.1.1 Europe Recombinant Insulin Analogue Sales by Type (2017-2028)
7.1.2 Europe Recombinant Insulin Analogue Revenue by Type (2017-2028)
7.2 Europe Recombinant Insulin Analogue Market Size by Application
7.2.1 Europe Recombinant Insulin Analogue Sales by Application (2017-2028)
7.2.2 Europe Recombinant Insulin Analogue Revenue by Application (2017-2028)
7.3 Europe Recombinant Insulin Analogue Market Size by Country
7.3.1 Europe Recombinant Insulin Analogue Sales by Country (2017-2028)
7.3.2 Europe Recombinant Insulin Analogue Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Recombinant Insulin Analogue Market Size by Type
8.1.1 Asia Pacific Recombinant Insulin Analogue Sales by Type (2017-2028)
8.1.2 Asia Pacific Recombinant Insulin Analogue Revenue by Type (2017-2028)
8.2 Asia Pacific Recombinant Insulin Analogue Market Size by Application
8.2.1 Asia Pacific Recombinant Insulin Analogue Sales by Application (2017-2028)
8.2.2 Asia Pacific Recombinant Insulin Analogue Revenue by Application (2017-2028)
8.3 Asia Pacific Recombinant Insulin Analogue Market Size by Region
8.3.1 Asia Pacific Recombinant Insulin Analogue Sales by Region (2017-2028)
8.3.2 Asia Pacific Recombinant Insulin Analogue Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Recombinant Insulin Analogue Market Size by Type
9.1.1 Latin America Recombinant Insulin Analogue Sales by Type (2017-2028)
9.1.2 Latin America Recombinant Insulin Analogue Revenue by Type (2017-2028)
9.2 Latin America Recombinant Insulin Analogue Market Size by Application
9.2.1 Latin America Recombinant Insulin Analogue Sales by Application (2017-2028)
9.2.2 Latin America Recombinant Insulin Analogue Revenue by Application (2017-2028)
9.3 Latin America Recombinant Insulin Analogue Market Size by Country
9.3.1 Latin America Recombinant Insulin Analogue Sales by Country (2017-2028)
9.3.2 Latin America Recombinant Insulin Analogue Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Recombinant Insulin Analogue Market Size by Type
10.1.1 Middle East and Africa Recombinant Insulin Analogue Sales by Type (2017-2028)
10.1.2 Middle East and Africa Recombinant Insulin Analogue Revenue by Type (2017-2028)
10.2 Middle East and Africa Recombinant Insulin Analogue Market Size by Application
10.2.1 Middle East and Africa Recombinant Insulin Analogue Sales by Application (2017-2028)
10.2.2 Middle East and Africa Recombinant Insulin Analogue Revenue by Application (2017-2028)
10.3 Middle East and Africa Recombinant Insulin Analogue Market Size by Country
10.3.1 Middle East and Africa Recombinant Insulin Analogue Sales by Country (2017-2028)
10.3.2 Middle East and Africa Recombinant Insulin Analogue Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Novo Nordisk A/S
11.1.1 Novo Nordisk A/S Corporation Information
11.1.2 Novo Nordisk A/S Overview
11.1.3 Novo Nordisk A/S Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Novo Nordisk A/S Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novo Nordisk A/S Recent Developments
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Corporation Information
11.2.2 Eli Lilly and Company Overview
11.2.3 Eli Lilly and Company Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Eli Lilly and Company Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Eli Lilly and Company Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Sanofi Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Gan & Lee Pharmaceuticals Co., Ltd
11.4.1 Gan & Lee Pharmaceuticals Co., Ltd Corporation Information
11.4.2 Gan & Lee Pharmaceuticals Co., Ltd Overview
11.4.3 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Gan & Lee Pharmaceuticals Co., Ltd Recent Developments
11.5 The United Laboratories International Holdings Limited
11.5.1 The United Laboratories International Holdings Limited Corporation Information
11.5.2 The United Laboratories International Holdings Limited Overview
11.5.3 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 The United Laboratories International Holdings Limited Recent Developments
11.6 Tonghua Dongbao Pharmaceutical Co., Ltd
11.6.1 Tonghua Dongbao Pharmaceutical Co., Ltd Corporation Information
11.6.2 Tonghua Dongbao Pharmaceutical Co., Ltd Overview
11.6.3 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Recombinant Insulin Analogue Industry Chain Analysis
12.2 Recombinant Insulin Analogue Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Recombinant Insulin Analogue Production Mode & Process
12.4 Recombinant Insulin Analogue Sales and Marketing
12.4.1 Recombinant Insulin Analogue Sales Channels
12.4.2 Recombinant Insulin Analogue Distributors
12.5 Recombinant Insulin Analogue Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Recombinant Insulin Analogue Industry Trends
13.2 Recombinant Insulin Analogue Market Drivers
13.3 Recombinant Insulin Analogue Market Challenges
13.4 Recombinant Insulin Analogue Market Restraints
14 Key Findings in The Global Recombinant Insulin Analogue Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global Recombinant Insulin Analogue Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Quick-Acting
Table 3. Major Manufacturers of Medium Effect
Table 4. Major Manufacturers of Long-Lasting
Table 5. Major Manufacturers of Super Long-Acting
Table 6. Global Recombinant Insulin Analogue Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Recombinant Insulin Analogue Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Recombinant Insulin Analogue Sales by Region (2017-2022) & (K Units)
Table 9. Global Recombinant Insulin Analogue Sales Market Share by Region (2017-2022)
Table 10. Global Recombinant Insulin Analogue Sales by Region (2023-2028) & (K Units)
Table 11. Global Recombinant Insulin Analogue Sales Market Share by Region (2023-2028)
Table 12. Global Recombinant Insulin Analogue Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Recombinant Insulin Analogue Revenue Market Share by Region (2017-2022)
Table 14. Global Recombinant Insulin Analogue Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Recombinant Insulin Analogue Revenue Market Share by Region (2023-2028)
Table 16. Global Recombinant Insulin Analogue Sales by Manufacturers (2017-2022) & (K Units)
Table 17. Global Recombinant Insulin Analogue Sales Share by Manufacturers (2017-2022)
Table 18. Global Recombinant Insulin Analogue Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Recombinant Insulin Analogue Revenue Share by Manufacturers (2017-2022)
Table 20. Recombinant Insulin Analogue Price by Manufacturers (2017-2022) &(US$/Unit)
Table 21. Global Recombinant Insulin Analogue Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Recombinant Insulin Analogue by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Insulin Analogue as of 2021)
Table 23. Recombinant Insulin Analogue Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Recombinant Insulin Analogue Product Offered
Table 25. Date of Manufacturers Enter into Recombinant Insulin Analogue Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Recombinant Insulin Analogue Sales by Type (2017-2022) & (K Units)
Table 28. Global Recombinant Insulin Analogue Sales by Type (2023-2028) & (K Units)
Table 29. Global Recombinant Insulin Analogue Sales Share by Type (2017-2022)
Table 30. Global Recombinant Insulin Analogue Sales Share by Type (2023-2028)
Table 31. Global Recombinant Insulin Analogue Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Recombinant Insulin Analogue Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Recombinant Insulin Analogue Revenue Share by Type (2017-2022)
Table 34. Global Recombinant Insulin Analogue Revenue Share by Type (2023-2028)
Table 35. Recombinant Insulin Analogue Price by Type (2017-2022) & (US$/Unit)
Table 36. Global Recombinant Insulin Analogue Price Forecast by Type (2023-2028) & (US$/Unit)
Table 37. Global Recombinant Insulin Analogue Sales by Application (2017-2022) & (K Units)
Table 38. Global Recombinant Insulin Analogue Sales by Application (2023-2028) & (K Units)
Table 39. Global Recombinant Insulin Analogue Sales Share by Application (2017-2022)
Table 40. Global Recombinant Insulin Analogue Sales Share by Application (2023-2028)
Table 41. Global Recombinant Insulin Analogue Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Recombinant Insulin Analogue Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Recombinant Insulin Analogue Revenue Share by Application (2017-2022)
Table 44. Global Recombinant Insulin Analogue Revenue Share by Application (2023-2028)
Table 45. Recombinant Insulin Analogue Price by Application (2017-2022) & (US$/Unit)
Table 46. Global Recombinant Insulin Analogue Price Forecast by Application (2023-2028) & (US$/Unit)
Table 47. North America Recombinant Insulin Analogue Sales by Type (2017-2022) & (K Units)
Table 48. North America Recombinant Insulin Analogue Sales by Type (2023-2028) & (K Units)
Table 49. North America Recombinant Insulin Analogue Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Recombinant Insulin Analogue Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Recombinant Insulin Analogue Sales by Application (2017-2022) & (K Units)
Table 52. North America Recombinant Insulin Analogue Sales by Application (2023-2028) & (K Units)
Table 53. North America Recombinant Insulin Analogue Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Recombinant Insulin Analogue Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Recombinant Insulin Analogue Sales by Country (2017-2022) & (K Units)
Table 56. North America Recombinant Insulin Analogue Sales by Country (2023-2028) & (K Units)
Table 57. North America Recombinant Insulin Analogue Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Recombinant Insulin Analogue Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Recombinant Insulin Analogue Sales by Type (2017-2022) & (K Units)
Table 60. Europe Recombinant Insulin Analogue Sales by Type (2023-2028) & (K Units)
Table 61. Europe Recombinant Insulin Analogue Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Recombinant Insulin Analogue Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Recombinant Insulin Analogue Sales by Application (2017-2022) & (K Units)
Table 64. Europe Recombinant Insulin Analogue Sales by Application (2023-2028) & (K Units)
Table 65. Europe Recombinant Insulin Analogue Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Recombinant Insulin Analogue Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Recombinant Insulin Analogue Sales by Country (2017-2022) & (K Units)
Table 68. Europe Recombinant Insulin Analogue Sales by Country (2023-2028) & (K Units)
Table 69. Europe Recombinant Insulin Analogue Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Recombinant Insulin Analogue Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Recombinant Insulin Analogue Sales by Type (2017-2022) & (K Units)
Table 72. Asia Pacific Recombinant Insulin Analogue Sales by Type (2023-2028) & (K Units)
Table 73. Asia Pacific Recombinant Insulin Analogue Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Recombinant Insulin Analogue Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Recombinant Insulin Analogue Sales by Application (2017-2022) & (K Units)
Table 76. Asia Pacific Recombinant Insulin Analogue Sales by Application (2023-2028) & (K Units)
Table 77. Asia Pacific Recombinant Insulin Analogue Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Recombinant Insulin Analogue Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Recombinant Insulin Analogue Sales by Region (2017-2022) & (K Units)
Table 80. Asia Pacific Recombinant Insulin Analogue Sales by Region (2023-2028) & (K Units)
Table 81. Asia Pacific Recombinant Insulin Analogue Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Recombinant Insulin Analogue Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Recombinant Insulin Analogue Sales by Type (2017-2022) & (K Units)
Table 84. Latin America Recombinant Insulin Analogue Sales by Type (2023-2028) & (K Units)
Table 85. Latin America Recombinant Insulin Analogue Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Recombinant Insulin Analogue Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Recombinant Insulin Analogue Sales by Application (2017-2022) & (K Units)
Table 88. Latin America Recombinant Insulin Analogue Sales by Application (2023-2028) & (K Units)
Table 89. Latin America Recombinant Insulin Analogue Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Recombinant Insulin Analogue Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Recombinant Insulin Analogue Sales by Country (2017-2022) & (K Units)
Table 92. Latin America Recombinant Insulin Analogue Sales by Country (2023-2028) & (K Units)
Table 93. Latin America Recombinant Insulin Analogue Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Recombinant Insulin Analogue Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Recombinant Insulin Analogue Sales by Type (2017-2022) & (K Units)
Table 96. Middle East and Africa Recombinant Insulin Analogue Sales by Type (2023-2028) & (K Units)
Table 97. Middle East and Africa Recombinant Insulin Analogue Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Recombinant Insulin Analogue Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Recombinant Insulin Analogue Sales by Application (2017-2022) & (K Units)
Table 100. Middle East and Africa Recombinant Insulin Analogue Sales by Application (2023-2028) & (K Units)
Table 101. Middle East and Africa Recombinant Insulin Analogue Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Recombinant Insulin Analogue Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Recombinant Insulin Analogue Sales by Country (2017-2022) & (K Units)
Table 104. Middle East and Africa Recombinant Insulin Analogue Sales by Country (2023-2028) & (K Units)
Table 105. Middle East and Africa Recombinant Insulin Analogue Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Recombinant Insulin Analogue Revenue by Country (2023-2028) & (US$ Million)
Table 107. Novo Nordisk A/S Corporation Information
Table 108. Novo Nordisk A/S Description and Major Businesses
Table 109. Novo Nordisk A/S Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 110. Novo Nordisk A/S Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Novo Nordisk A/S Recent Developments
Table 112. Eli Lilly and Company Corporation Information
Table 113. Eli Lilly and Company Description and Major Businesses
Table 114. Eli Lilly and Company Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 115. Eli Lilly and Company Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Eli Lilly and Company Recent Developments
Table 117. Sanofi Corporation Information
Table 118. Sanofi Description and Major Businesses
Table 119. Sanofi Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 120. Sanofi Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Sanofi Recent Developments
Table 122. Gan & Lee Pharmaceuticals Co., Ltd Corporation Information
Table 123. Gan & Lee Pharmaceuticals Co., Ltd Description and Major Businesses
Table 124. Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 125. Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Gan & Lee Pharmaceuticals Co., Ltd Recent Developments
Table 127. The United Laboratories International Holdings Limited Corporation Information
Table 128. The United Laboratories International Holdings Limited Description and Major Businesses
Table 129. The United Laboratories International Holdings Limited Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 130. The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. The United Laboratories International Holdings Limited Recent Developments
Table 132. Tonghua Dongbao Pharmaceutical Co., Ltd Corporation Information
Table 133. Tonghua Dongbao Pharmaceutical Co., Ltd Description and Major Businesses
Table 134. Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 135. Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments
Table 137. Key Raw Materials Lists
Table 138. Raw Materials Key Suppliers Lists
Table 139. Recombinant Insulin Analogue Distributors List
Table 140. Recombinant Insulin Analogue Customers List
Table 141. Recombinant Insulin Analogue Market Trends
Table 142. Recombinant Insulin Analogue Market Drivers
Table 143. Recombinant Insulin Analogue Market Challenges
Table 144. Recombinant Insulin Analogue Market Restraints
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Insulin Analogue Product Picture
Figure 2. Global Recombinant Insulin Analogue Market Share by Type in 2021 & 2028
Figure 3. Quick-Acting Product Picture
Figure 4. Medium Effect Product Picture
Figure 5. Long-Lasting Product Picture
Figure 6. Super Long-Acting Product Picture
Figure 7. Global Recombinant Insulin Analogue Market Share by Application in 2021 & 2028
Figure 8. Type 1 Diabetes
Figure 9. Type 2 Diabetes
Figure 10. Recombinant Insulin Analogue Report Years Considered
Figure 11. Global Recombinant Insulin Analogue Sales 2017-2028 (K Units)
Figure 12. Global Recombinant Insulin Analogue Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Recombinant Insulin Analogue Revenue 2017-2028 (US$ Million)
Figure 14. Global Recombinant Insulin Analogue Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Recombinant Insulin Analogue Sales Market Share by Region (2017-2022)
Figure 16. Global Recombinant Insulin Analogue Sales Market Share by Region (2023-2028)
Figure 17. North America Recombinant Insulin Analogue Sales YoY (2017-2028) & (K Units)
Figure 18. North America Recombinant Insulin Analogue Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Recombinant Insulin Analogue Sales YoY (2017-2028) & (K Units)
Figure 20. Europe Recombinant Insulin Analogue Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Recombinant Insulin Analogue Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific Recombinant Insulin Analogue Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Recombinant Insulin Analogue Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America Recombinant Insulin Analogue Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Recombinant Insulin Analogue Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa Recombinant Insulin Analogue Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Recombinant Insulin Analogue Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Recombinant Insulin Analogue in the World: Market Share by Recombinant Insulin Analogue Revenue in 2021
Figure 29. Global Recombinant Insulin Analogue Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Recombinant Insulin Analogue Sales Market Share by Type (2017-2028)
Figure 31. Global Recombinant Insulin Analogue Revenue Market Share by Type (2017-2028)
Figure 32. Global Recombinant Insulin Analogue Sales Market Share by Application (2017-2028)
Figure 33. Global Recombinant Insulin Analogue Revenue Market Share by Application (2017-2028)
Figure 34. North America Recombinant Insulin Analogue Sales Market Share by Type (2017-2028)
Figure 35. North America Recombinant Insulin Analogue Revenue Market Share by Type (2017-2028)
Figure 36. North America Recombinant Insulin Analogue Sales Market Share by Application (2017-2028)
Figure 37. North America Recombinant Insulin Analogue Revenue Market Share by Application (2017-2028)
Figure 38. North America Recombinant Insulin Analogue Sales Share by Country (2017-2028)
Figure 39. North America Recombinant Insulin Analogue Revenue Share by Country (2017-2028)
Figure 40. United States Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Recombinant Insulin Analogue Sales Market Share by Type (2017-2028)
Figure 43. Europe Recombinant Insulin Analogue Revenue Market Share by Type (2017-2028)
Figure 44. Europe Recombinant Insulin Analogue Sales Market Share by Application (2017-2028)
Figure 45. Europe Recombinant Insulin Analogue Revenue Market Share by Application (2017-2028)
Figure 46. Europe Recombinant Insulin Analogue Sales Share by Country (2017-2028)
Figure 47. Europe Recombinant Insulin Analogue Revenue Share by Country (2017-2028)
Figure 48. Germany Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 49. France Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Recombinant Insulin Analogue Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Recombinant Insulin Analogue Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Recombinant Insulin Analogue Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Recombinant Insulin Analogue Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Recombinant Insulin Analogue Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Recombinant Insulin Analogue Revenue Share by Region (2017-2028)
Figure 59. China Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 62. India Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Recombinant Insulin Analogue Sales Market Share by Type (2017-2028)
Figure 69. Latin America Recombinant Insulin Analogue Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Recombinant Insulin Analogue Sales Market Share by Application (2017-2028)
Figure 71. Latin America Recombinant Insulin Analogue Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Recombinant Insulin Analogue Sales Share by Country (2017-2028)
Figure 73. Latin America Recombinant Insulin Analogue Revenue Share by Country (2017-2028)
Figure 74. Mexico Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 77. Colombia Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Recombinant Insulin Analogue Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Recombinant Insulin Analogue Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Recombinant Insulin Analogue Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Recombinant Insulin Analogue Revenue Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Recombinant Insulin Analogue Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Recombinant Insulin Analogue Revenue Share by Country (2017-2028)
Figure 84. Turkey Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Recombinant Insulin Analogue Revenue (2017-2028) & (US$ Million)
Figure 87. Recombinant Insulin Analogue Value Chain
Figure 88. Recombinant Insulin Analogue Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed